[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypertrophic-cardiomyopathy-without-obstruction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypertrophic-cardiomyopathy-without-obstruction":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,82],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100639237","exercise-prescription-in-children-with-hypertrophic-cardiomyopathy-100639237",false,"NCT07595354","Exercise Prescription in Children With Hypertrophic Cardiomyopathy","Effects of Exercise Prescription on Cardiovascular Health and Quality of Life in Children With Hypertrophic Cardiomyopathy","Empower","Inclusion Criteria:\n\n* Undergoing screening for HCM due to a family history or gene-positive\n* Aged 10 to 18 years (inclusive)\n* Known to the inherited cardiac conditions clinic at Alder Hey Children's Hospital\n* Normal cardiac function\n* Able to complete an exercise log weekly with support from carers\n* Child or carer able to participate in telephone follow-up\n\nExclusion Criteria:\n\n* Moderate to severe co-morbidities, including neuromuscular and respiratory illness and conditions affecting mobility\n* Learning difficulties precluding exercise participation\n* Phenotype of HCM\n* History of exercise-induced arrhythmia and\u002For syncope\n* History of unexplained syncope\n* Patients with an implantable cardiac defibrillator (ICD)\n* Family History of sudden cardiac death in first-degree relative\n* Child or carer unable to comply with telephone follow-up","ALL","10 Years","18 Years",{"count":21,"type":22},10,"ESTIMATED","INTERVENTIONAL",[25],"NA","Hypertrophic Cardiomyopathy (HCM) is an inherited cardiac condition that affects the heart muscle of adults and children. Historically, doctors have been cautious about encouraging patients with HCM to exercise, as they were worried it could be unsafe due to the risk of heart problems or emergencies. But recent evidence shows that the risks of exercise for a patient with HCM are far lower than previously thought and exercise has many benefits for a child's general health and mental well-being and is an important part of their social development.\n\nOne way to help children with HCM feel confident to exercise is with an individualised exercise 'prescription'. This is where a team of specialist doctors, nurses, and physiotherapists assess patients and advise them on how to exercise safely and effectively. They then provide an exercise plan or 'prescription' individualised to them.\n\nThis study aims to establish whether the investigators can deliver an individualised exercise prescription (IEP) service for children with HCM who attend outpatient cardiology. A further aim is to see if children will want to take part and adhere to the IEP.\n\nIn this study children aged 10 to 18 years old attending outpatient cardiology clinic at Alder Hey Children's Hospital (AHCH) under screening for HCM will be asked if they wish to take part in the study. Those who wish to take part will have extra appointments at AHCH, during which the investigators will measure their height and weight. They will also have other tests done like blood pressure, a cycle test, sit-to-stand test, measurement of their hamstring flexibility and an ultrasound measure of their thigh muscle.\n\nThe participants will be asked to complete a questionnaire about their quality of life. The participants will then be given an individualised exercise plan. In the first month, they will be given a supervised exercise session and asked to record their activity levels in an exercise log.\n\nThe participants will have either a monthly telephone call or a face-to-face visit to see how they are getting on. After 6 months, all the initial tests will be repeated. The investigators will look at the data to see if the exercise prescription was helpful, if children could stick to it and if there have been improvements in their fitness and quality of life. Finally, the investigators will see them again six months later to see if the IEP programme has had a lasting impact on their exercise levels, fitness, and well-being.",[28],"Hypertrophic Cardiomyopathy Without Obstruction",[30,31,32,33],"Exercise Prescription","Feasability","Hypertrophic Cardiomyopathy","Children","RECRUITING","2026-05-12",{"date":37,"type":38},"2026-05-19","ACTUAL",{"date":40,"type":38},"2025-12-24",{"date":42,"type":22},"2027-08",{"name":44,"class":45},"Alder Hey Children's NHS Foundation Trust","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":55,"targetDuration":57,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":46},"100625305","study-of-the-progression-of-chronic-cardiovascular-conditions-100625305","NCT07420907","Study of the Progression of Chronic Cardiovascular Conditions","A Non-interventional Observational Study of the Sustained Use of Prolaio Digital Health Devices to Monitor the Natural History of Chronic Cardiovascular Conditions in Ambulatory Patients","OCORO","Inclusion Criteria:\n\n* 18 years of age and older\n* Ability to understand study assessments and give informed consent to data collection\n* Ability to comply with the study protocol\n* Ability to understand and respond to instructions in English\n* Has diagnosis of qualifying Cardiovascular Disease(s) (CVD) including but not limited to: HF, AS, HCM, HTN, DCM, etc.\n* Resides in the United States\n\nExclusion Criteria:\n\n* Allergy to adhesive used in biosensor patch\n* Life threatening disease process outside of area under study, such as actively treated cancer or pre\u002Fpost-transplant such as hepatic failure; end-stage renal disease.\n* Severe CVD defined by hospital admission for cardiac diagnosis within 30 days of enrollment or documentation of NYHA functional class IV\n* Self-reported weight of 400 pounds or greater",{"count":56,"type":22},5000,"5 Years","OBSERVATIONAL","This study will collect physiologic data in patients with cardiovascular conditions and observe the natural history of those conditions for research purposes.",[61,62,63,64,65,66,67,28,68,69,70,71],"Cardiovascular Disease (CVD)","Heart Failure","Aortic Stenosis","Aortic Stenosis Disease","Hypertension","Hypertension (HTN)","Hypertrophic Cardiomyopathy Patients","Hypertrophic Cardiomyopathy, Obstructive","Dilated Cardiomyopathy (DCM)","Dilated Cardiomyopathy","Dilated Cardiomyopathy, Familial","2026-02-16",{"date":74,"type":38},"2026-02-19",{"date":76,"type":38},"2025-10-30",{"date":78,"type":22},"2030-10",{"name":80,"class":81},"Prolaio","INDUSTRY",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":23,"phases":91,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":46},"100549364","early-phase-1-sodium-glucose-co-transporter-sglt-inhibitors-in-nonobstructive-hypertrophic-cardiomyopathy-100549364","NCT06433050","Sodium Glucose Co-transporter (SGLT) Inhibitors in Nonobstructive Hypertrophic Cardiomyopathy","SOTA-CROSS HCM","Inclusion Criteria:\n\n1. Age at least 18 years, both sexes\n2. Provision of signed and dated informed consent form\n3. Stated willingness to comply with all study procedures and availability for the duration of the study\n4. Ability to take oral medication and be willing to adhere to the study intervention.\n5. For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 2 weeks after the end of administration of study drug.\n6. Diagnosis of HCM with NYHA Class II-III functional class or New York Heart Association (NYHA) Class I with peak VO2 \\\u003C 90% on cardiopulmonary exercise stress testing performed at Visit 1.\n7. Left ventricular outflow tract gradient \\\u003C 50 mmHg at rest, with valsalva, and with exercise.\n\n7\\. Left ventricular ejection fraction \\> 50% by echocardiogram or cardiac MRI based on the most recent assessment in the past year prior to screening and confirmed during Visit 1 echocardiogram.\n\n8\\. Stable medical therapy for at least 1 month prior to study enrollment.\n\nExclusion Criteria:\n\n1. Receiving therapy with an SGLT2 inhibitor within 8 weeks prior to enrollment or previous intolerance of an SGLT2 inhibitor\n2. Type 1 diabetes mellitus\n3. Age \\\u003C18 years old\n4. Pregnant or lactating women: Women of childbearing potential will undergo a urine pregnancy test during the screening visit.\n5. Uncontrolled atrial fibrillation, as defined by a resting heart rate \\> 100 beats per minute at the time of the baseline assessment\n6. Paroxysmal atrial fibrillation (Afib) or flutter with plans to attempt to restore sinus rhythm (with drug therapy, ablation, or DC cardioversion) during the study period.\n7. Unable to attain a respiratory exchange ratio of at least 1.05 on cardiopulmonary exercise test (CPET) on the day of screening.\n8. Septal reduction therapy within the previous 3 months.\n9. Implantable cardio-defibrillator (ICD) implantation planned during the study period.\n10. Implantation of a cardiac resynchronization therapy (CRT) device within 12 weeks prior to enrollment or intent to implant a CRT device during the study period\n11. Hemoglobin \\\u003C 10 g\u002FdL\n12. Estimated glomerular filtration rate (eGFR) \\\u003C 25 mL\u002Fmin\u002F1.73m\\^2, or unstable or rapidly progressing renal disease at the time of randomization\n13. Subject inability\u002Funwillingness to exercise\n14. Greater than moderate left sided valvular disease (mitral regurgitation, aortic stenosis, aortic regurgitation), moderate or greater mitral stenosis, or severe right-sided valvular disease based on baseline echo at the time of enrollment\n15. Current angina due to clinically significant epicardial coronary disease, as per investigator judgment\n16. Acute coronary syndrome or coronary intervention within the past 2 months\n17. Primary pulmonary artery hypertension (WHO Group 1 Pulmonary Arterial Hypertension)\n18. Clinically significant lung disease as defined by: Chronic Obstructive Pulmonary Disease meeting Stage III or greater GOLD criteria (FEV1\\\u003C50% predicted), treatment with oral steroids within the past 6 months for an exacerbation of obstructive lung disease, or current use of supplemental oxygen aside from nocturnal oxygen for the treatment of obstructive sleep apnea.\n19. Clinically-significant ischemia, as per investigator's judgement, on stress testing without either (1) subsequent revascularization, (2) an angiogram demonstrating the absence of clinically significant epicardial coronary artery disease, as per investigator judgment; (3) a follow-up 'negative' stress test, particularly when using a more specific technique (i.e., a negative perfusion imaging test following a 'positive' ECG stress test)\n20. Symptomatic bradycardia or second- or third-degree heart block, in the absence of a pacemaker\n21. Significant liver disease impacting synthetic function or volume control (ALT\u002FAST \\> 3x ULN, Albumin \\\u003C 3.0 g\u002FdL)\n22. Severe right ventricular dysfunction on baseline echocardiogram\n23. Orthostatic blood pressure response to the transition from supine to standing (\\>20 mmHg reduction in systolic blood pressure 2-3 minutes after standing)\n24. Active participation in another study that utilizes an investigational agent (observational studies\u002Fregistries allowed)\n25. Any condition that, in the opinion of the investigator, will interfere with the completion of the study. This may include comorbid or psychiatric conditions that may impede successful completion of the protocol, or logistical concerns (e.g. inability to travel to the exercise unit).",{"count":90,"type":22},26,[92],"EARLY_PHASE1","The goal of this clinical trial is to learn if sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, works to treat symptomatic, nonobstructive hypertrophic cardiomyopathy (noHCM) in adult patients. It will also learn about the safety of sotagliflozin in this patient population. The main questions it aims to answer are:\n\n1. Will sotagliflozin be well tolerated in patients with nonobstructive HCM?\n2. Will sotaglifozin improve exercise capacity, diastolic dysfunction and\u002For physical functioning in patients with nonobstructive HCM?\n3. Will sotagliflozin improve circulating markers of cardiac metabolism in patients with nonobstructive HCM?\n\nResearchers will compare sotagliflozin to a placebo (a look-alike substance that contains no drug) to see if sotagliflozin is effective at treating hypertrophic cardiomyopathy (HCM).\n\nParticipants will:\n\nTake sotagliflozin or a placebo every day for 12 weeks. They will then cross-over (or switch) to taking placebo or sotagliflozin (whichever one they did not take initially) for an additional 12 weeks.\n\nVisit the clinic once every 4-12 weeks for checkups, surveys, and tests including a stress test and echocardiogram.",[28],"2026-02-10",{"date":97,"type":38},"2026-02-11",{"date":99,"type":38},"2024-12-17",{"date":101,"type":22},"2027-06",{"name":103,"class":45},"University of Pennsylvania"]